Takayasu
Veille bibliographique : Artérite de Takayasu
Les articles sont classés du plus ancien au plus récent, n’hésitez pas à utiliser la barre de recherche pour filtrer les résultats par date par exemple.
| Langford CA et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol Hoboken NJ. 2017 Jan 30 | Lire le résumé |
| Assad AP et al. Maternal and Neonatal Outcomes in 89 Patients with Takayasu Arteritis (TA): Comparison Before and After the TA Diagnosis. J Rheumatol. 2015 Oct;42(10):1861-4 | Lire le résumé |
| Gudbrandsson B et al. Takayasu Arteritis and Pregnancy: A Population-Based Study on Outcomes and Mother/Child-Related Concerns. Arthritis Care Res. 2017 Sep;69(9):1384–90. | Lire le résumé |
| Kong X, Sawalha AH. Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2–HDAC complex. Ann Rheum Dis. oct 2019;78(10):1388 97. (PubMed)Kong X, Sawalha AH. Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2–HDAC complex. Ann Rheum Dis. oct 2019;78(10):1388 97 | Lire le résumé |
| Gribbons KB, Ponte C, Carette S, Craven A, Cuthbertson D, Hoffman GS, et al. Patterns of Arterial Disease in Takayasu’s Arteritis and Giant Cell Arteritis. Arthritis Care Res [Internet]. 23 août 2019 [cité 15 oct 2019]; | Lire le résumé |
| Michailidou D, Rosenblum JS, Rimland CA, Marko J, Ahlman MA, Grayson PC. Clinical symptoms and associated vascular imaging findings in Takayasu’s arteritis compared to giant cell arteritis. Ann Rheum Dis. 24 oct 2019;annrheumdis-2019-216145 | Lire le résumé |
| Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology [Internet]. 17 janv 2020 [cité 24 janv 2020] | Lire le résumé |
| Campochiaro C, Tomelleri A, Sartorelli S, Cavalli G et al. Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. Semin Arthritis Rheum. 2020 Jan 25 | Lire le résumé |
| Cui X, Dai X, Ma L, Yang C, Tan W, Zhang L, et al. Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. Semin Arthritis Rheum. févr 2020;50(1):59‑65 | Lire le résumé |
| Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol. août 2021;73(8):1349‑65. | Lire le résumé |